GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Last update: 29 Dec, 2025, 12:02PM

124.42

-0.28 (-0.22%)

  • 1D -0.22%
  • 5D 0.06%
  • 1M -0.62%
  • 6M 9.56%
  • YTD 2.32%
  • 1Y 33.90%
  • 5Y 82.54%
Previous Close 124.70
Open 124.78
Volume 955,685
Avg. Volume (3M) 7,389,553
Market Cap 154,381,189,120
Price / Earnings (TTM) 19.26
Price / Earnings (Forward) 14.20
Price / Sales 5.42
Price / Book 7.19
52 Weeks Range
88.57 (-28%) — 128.70 (3%)
Earnings Date 10 Feb 2026
TTM Dividend Yield 2.54%
Profit Margin 20.76%
Operating Margin (TTM) 38.49%
Diluted EPS (TTM) 4.76
Quarterly Revenue Growth (YOY) -0.30%
Quarterly Earnings Growth (YOY) 24.80%
Total Debt/Equity (MRQ) 130.79%
Current Ratio (MRQ) 1.37
Operating Cash Flow (TTM) 10.37 B
Levered Free Cash Flow (TTM) 9.99 B
Return on Assets (TTM) 12.14%
Return on Equity (TTM) 32.65%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Mixed
Drug Manufacturers - General (Global) Bullish Mixed
Stock Gilead Sciences, Inc. Bullish Bullish

AIStockmoo Score

0.4
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -0.5
Technical Moving Averages 2.5
Technical Oscillators -2.0
Average 0.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
GILD 154 B 2.54% 19.26 7.19
AMGN 173 B 2.97% 24.80 18.50
AZN 284 B 1.71% 30.63 6.38
SNY 117 B 4.57% 15.70 1.34
BIIB 26 B - 15.93 1.51
GRFS 8 B 1.88% 14.44 1.01

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.10%
% Held by Institutions 89.79%
52 Weeks Range
88.57 (-28%) — 128.70 (3%)
Price Target Range
105.00 (-15%) — 150.00 (20%)
High 150.00 (Morgan Stanley, 20.56%) Buy
150.00 (Wells Fargo, 20.56%) Buy
150.00 (JP Morgan, 20.56%) Buy
Median 140.00 (12.52%)
Low 105.00 (RBC Capital, -15.61%) Hold
Average 138.18 (11.06%)
Total 10 Buy, 1 Hold
Avg. Price @ Call 122.51
Firm Date Target Price Call Price @ Call
Morgan Stanley 13 Jan 2026 150.00 (20.56%) Buy 121.76
12 Dec 2025 151.00 (21.36%) Buy 120.40
Citigroup 07 Jan 2026 140.00 (12.52%) Buy 124.35
UBS 07 Jan 2026 145.00 (16.54%) Buy 124.35
Wells Fargo 10 Dec 2025 150.00 (20.56%) Buy 121.34
31 Oct 2025 145.00 (16.54%) Buy 119.79
Truist Securities 24 Nov 2025 140.00 (12.52%) Buy 125.27
03 Nov 2025 145.00 (16.54%) Buy 122.05
Needham 13 Nov 2025 140.00 (12.52%) Buy 125.20
31 Oct 2025 133.00 (6.90%) Buy 119.79
Scotiabank 13 Nov 2025 140.00 (12.52%) Buy 125.20
Cantor Fitzgerald 31 Oct 2025 135.00 (8.50%) Buy 119.79
JP Morgan 31 Oct 2025 150.00 (20.56%) Buy 119.79
RBC Capital 31 Oct 2025 105.00 (-15.61%) Hold 119.79
TD Cowen 23 Oct 2025 125.00 (0.47%) Buy 120.74
Show more

No data within this time range.

  • 3M
Date Type Details
06 Jan 2026 Announcement OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate
22 Dec 2025 Announcement Gilead Sciences to Present at Upcoming Investor Conference
22 Dec 2025 Announcement Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
19 Dec 2025 Announcement Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
18 Dec 2025 Announcement Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
15 Dec 2025 Announcement Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
09 Dec 2025 Announcement Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
07 Dec 2025 Announcement Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
06 Dec 2025 Announcement Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
06 Dec 2025 Announcement Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
24 Nov 2025 Announcement Gilead Foundation Commits Over $3 Million to Address Food Insecurity
20 Nov 2025 Announcement Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
18 Nov 2025 Announcement Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
13 Nov 2025 Announcement Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
07 Nov 2025 Announcement Gilead Provides Update on Phase 3 ASCENT-07 Study
07 Nov 2025 Announcement Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
04 Nov 2025 Announcement Gilead Sciences to Present at Upcoming Investor Conferences
03 Nov 2025 Announcement Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
31 Oct 2025 Announcement Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
30 Oct 2025 Announcement Gilead Sciences Announces Third Quarter 2025 Financial Results
23 Oct 2025 Announcement Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
Show more
TTM Dividend Yield 2.54%
5Y Average Dividend Yield 3.38%
Payout Ratio 65.13%
Expected Next Dividend Payment Mar 2026
Ex Date Announcement Date Payment Date Details
15 Dec 2025 28 Oct 2025 30 Dec 2025 0.79 Cash
15 Sep 2025 29 Jul 2025 29 Sep 2025 0.79 Cash
13 Jun 2025 22 Apr 2025 27 Jun 2025 0.79 Cash
14 Mar 2025 05 Feb 2025 28 Mar 2025 0.79 Cash
13 Dec 2024 30 Oct 2024 30 Dec 2024 0.77 Cash
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 Cash
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 Cash
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 Cash
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 Cash
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 Cash
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 Cash
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 Cash
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 Cash
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 Cash
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 Cash
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 Cash
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 Cash
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 Cash
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 Cash
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 Cash
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 Cash
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 Cash
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 Cash
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 Cash
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 Cash
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 Cash
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 Cash
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 Cash
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 Cash
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 Cash
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 Cash
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 Cash
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 Cash
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 Cash
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 Cash
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 Cash
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 Cash
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 Cash
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 Cash
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 Cash
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 Cash
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 Cash
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 3.16 4 2.58
2024 3.08 4 3.33
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria